Alumis Inc. Common Stock ALMS
$10.36
+9.35%
at last close
Market Cap$1.23 billion
P/E Ratio—
Div Yield—
Volume7.84M
52-Week Range
$3.76$31.35
Analyst Ratings
- Consensus
- Buy — 9 Buy · 0 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $33.56 (+224.1% upside)
Key Stats
- Today's Range
- $9.95 – $10.77
- 50-Day Range
- $8.75 – $31.35
- 52-Week Range
- $3.76 – $31.35
- Volume
- 7.84 million shs
- Average Volume
- 2.04 million shs
- Market Cap
- $1.23 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.71
- Price / Sales
- 165.69
Short Interest
- Short Interest
- 0.47%
- Days to Cover
- 3.15
Financials (TTM)
- Revenue
- $7.40 million
- Net Income
- $-438,957,000
- Net Margin
- -5933.45%
- Return on Equity
- -97.08%
- Debt-to-Equity
- —
About Alumis Inc. Common Stock
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Related Stocks
Compare head-to-head: ALMS vs LLY·ALMS vs JNJ·ALMS vs ABBV·ALMS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.